ArticleArchives of virology2025
Epidemiological status and genome characteristics of canine parvovirus in China from 2022 to 2024.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular Characteristics and Genetic Diversity of Canine Parvovirus in Shanghai, China, from 2016 to 2025.Microorganisms · 2026Article
- Development of canine parvovirus-neutralizing monoclonal antibodies from natural host and their germline gene usage.Applied microbiology and biotechnology · 2026Article
- Identification and Characterization of Canine Parvoviruses and Emergence of Canine Bocavirus and Bufavirus from Diarrheic Dogs in Sichuan Province, China.Veterinary sciences · 2026Article
- Leveraging single B cell antibody platforms to develop countermeasures against animal viral diseases: recent advances and future perspectives.Frontiers in veterinary science · 2026Review
- Parvoviruses at the Heart: Endothelial Injury and Myocyte Lysis in Human B19V and Canine CPV-2 Infections.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Canine parvovirus (CPV) is a highly contagious and lethal virus that primarily affects dogs. The virulence and transmissibility of this virus have intensified over time, posing significant challenges to the prevention and control of this pathogen. In this study, to investigate the epidemiology of CPV in China, 2,654 fecal samples were collected from seven provinces, and the positive rate was found to be 50.53%. The positive rates in Liaoning, Shandong, Hubei, Hunan, Guangxi, Jiangxi, and Fujian provinces were 78.53%, 9.25%, 58.37%, 3.00%, 42.68%, 78.26%, and 41.47%, respectively. Among these samples, four genotypes were identified: CPV-2 (4.42%), CPV-2c (69.04%), new CPV-2a (23.81%), and new CPV-2b (2.7%). Notably, CPV-2c emerged as the most prevalent genotype. Amino acid sequence alignments indicated that the main substitutions in VP2 were M87L, S297A, A300G, Y324I, N375D, and N426D/E, and the main substitutions in NS1 were I60V, Y544F, E545V, and L630P. Moreover, the mutations A5G, Q370R, and N426E were observed to be nearly universal among all CPV-2c strains, and I60V, Y544F, E545V were mainly found in CPV-2c and new CPV-2b strains. Phylogenetic analysis based on VP2 sequences revealed that CPV and FPV formed two distinct clusters. Furthermore, the CPV cluster was subdivided into four groups: CPV-2, CPV-2c, new CPV-2a, and new CPV-2b. However, the sub-branch of the NS1 evolutionary tree did not correspond strictly to the CPV genotype. In summary, our findings revealed significant variation in the prevalence of CPV across different regions in China. These findings carry significant implications for our understanding of CPV transmission dynamics and will play an important role in informing vaccine development strategies.
Indexed as
Identifiers
40350501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.